NASDAQ:FULC - Nasdaq - US3596161097 - Common Stock - Currency: USD
6.35
-0.09 (-1.4%)
The current stock price of FULC is 6.35 USD. In the past month the price increased by 77.87%. In the past year, price decreased by -19.11%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY | ELI LILLY & CO | 52.7 | 687.32B | ||
JNJ | JOHNSON & JOHNSON | 15.25 | 368.73B | ||
NVO | NOVO-NORDISK A/S-SPONS ADR | 19.68 | 312.99B | ||
NVS | NOVARTIS AG-SPONSORED ADR | 13.62 | 223.60B | ||
AZN | ASTRAZENECA PLC-SPONS ADR | 16.13 | 220.00B | ||
MRK | MERCK & CO. INC. | 9.96 | 194.83B | ||
PFE | PFIZER INC | 7.36 | 134.23B | ||
SNY | SANOFI-ADR | 11.83 | 127.50B | ||
BMY | BRISTOL-MYERS SQUIBB CO | 6.39 | 95.42B | ||
GSK | GSK PLC-SPON ADR | 8.86 | 80.03B | ||
ZTS | ZOETIS INC | 27.62 | 74.02B | ||
HLN | HALEON PLC-ADR | 22.92 | 50.57B |
Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 45 full-time employees. The company went IPO on 2019-07-18. The firm's lead clinical program is pociredir, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease (SCD). The company uses technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. In addition to its product candidates, the Company has developed a discovery approach that it employs to systematically identify and validate cellular drug targets that can potentially modulate gene expression to treat known root causes of genetically defined rare diseases. The firm continues to advance its program for the potential treatment of inherited aplastic anemias, such as Diamond-Blackfan anemia (DBA), Shwachman-Diamond syndrome, and Fanconi anemia.
FULCRUM THERAPEUTICS INC
26 Landsdowne Street
Cambridge MASSACHUSETTS 02139 US
CEO: Robert J. Gould
Employees: 45
Phone: 16176518851
The current stock price of FULC is 6.35 USD. The price decreased by -1.4% in the last trading session.
The exchange symbol of FULCRUM THERAPEUTICS INC is FULC and it is listed on the Nasdaq exchange.
FULC stock is listed on the Nasdaq exchange.
13 analysts have analysed FULC and the average price target is 5.44 USD. This implies a price decrease of -14.33% is expected in the next year compared to the current price of 6.35. Check the FULCRUM THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
FULCRUM THERAPEUTICS INC (FULC) has a market capitalization of 342.77M USD. This makes FULC a Small Cap stock.
FULCRUM THERAPEUTICS INC (FULC) currently has 45 employees.
FULCRUM THERAPEUTICS INC (FULC) has a support level at 6.11 and a resistance level at 6.85. Check the full technical report for a detailed analysis of FULC support and resistance levels.
The Revenue of FULCRUM THERAPEUTICS INC (FULC) is expected to decline by -100% in the next year. Check the estimates tab for more information on the FULC EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
FULC does not pay a dividend.
FULCRUM THERAPEUTICS INC (FULC) will report earnings on 2025-07-29, before the market open.
FULCRUM THERAPEUTICS INC (FULC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.07).
The outstanding short interest for FULCRUM THERAPEUTICS INC (FULC) is 6.45% of its float. Check the ownership tab for more information on the FULC short interest.
ChartMill assigns a technical rating of 9 / 10 to FULC. When comparing the yearly performance of all stocks, FULC is one of the better performing stocks in the market, outperforming 91.45% of all stocks.
ChartMill assigns a fundamental rating of 4 / 10 to FULC. FULC has a great financial health rating, but its profitability evaluates not so good.
Over the last trailing twelve months FULC reported a non-GAAP Earnings per Share(EPS) of -0.07. The EPS increased by 95.63% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -3.73% | ||
ROE | -4% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 74% to FULC. The Buy consensus is the average rating of analysts ratings from 13 analysts.
For the next year, analysts expect an EPS growth of -437.82% and a revenue growth -100% for FULC